Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group


Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.

Read the rest here:
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

Related Posts